SPR pH-Gradient Assay for Antibody Dissociation Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing SPR technologies struggle to effectively characterize pH-dependent interactions of antibodies with their antigens, limiting the optimization of antibody pharmacokinetics and dosage requirements.
Innovation Solution
A novel SPR-based assay that applies a pH-gradient to monitor the dissociation of antibodies from their antigens, allowing for the determination of pH-dependent binding activity, selection of pH-dependent antibodies, and analysis of dissociation rates and oligomerization effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional SPR technology is used to measure antibody-antigen binding, then binding constants can be determined, but pH-dependent interactions cannot be effectively characterized
Solution Approach 1:
The patent applies a pH-gradient to the SPR measurement system, dynamically changing the pH parameter from physiological pH (7.4) to acidic pH (5.8) to characterize pH-dependent antibody-antigen interactions. This allows determination of dissociation pH-values and differentiation of pH-sensitive binders, resolving the limitation of conventional SPR that cannot effectively measure pH-dependent binding.
2Reliability
If antibody affinity is increased to reduce dosage, then neutralization efficiency improves, but the requirement for higher antibody doses to sustain neutralization effect persists due to stoichiometric limitations
Solution Approach 1:
The patent introduces dynamic pH-gradient elution to the SPR assay, creating a dynamic measurement environment that reveals pH-dependent dissociation behavior. This enables identification of antibodies that can sustain binding under varying pH conditions, which is critical for maintaining neutralization effect throughout the gastrointestinal tract transit time, thereby reducing the required antibody dose.
3Duration of action of moving object
If a single antibody must neutralize multiple antigens to reduce dosage, then the neutralization period is extended, but the complexity of characterizing such pH-dependent behavior increases
Solution Approach 1:
The patent implements continuous pH-gradient elution throughout the measurement process, maintaining a steady progression from pH 7.4 to pH 5.8 without interruption. This continuous action allows real-time monitoring of antibody dissociation behavior across the pH spectrum, providing comprehensive characterization data that simplifies the understanding of pH-dependent binding mechanisms despite the extended measurement duration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the characterization of pH-dependent antibody-antigen interactions, facilitating the selection of antibodies with improved pharmacokinetics and reduced dosage requirements, and separation of low-pH-binding antibodies.
Implementation Method 1
SPR (surface plasmon resonance) is a biosensor-based technology to measure real time protein-protein interaction
Implementation Method 2
applying a pH-gradient from the first pH-value to a second pH-value to the solid phase and monitoring the dissociation of the antibody from the solid phase
Data Source
AI summary
Herein is reported a method for determining the dissociation rate constant kd of an antibody from its antigen at the dissociation pH-value, wherein the method comprises the steps of immobilizing at a first pH-value the antibody on a solid phase to which the antigen of the antibody has been conjugated; applying a pH-gradient from the first pH-value to the dissociation pH-value and thereafter maintaining the pH-value at said dissociation pH-value; and recording the binding signal during the maintaining of the pH-value and calculating therefrom the dissociation rate constant kd of the antibody from its antigen at the dissociation pH-value.